Bendamustine-d<sub>4</sub> (hydrochloride)

Bendamustine-d4 (hydrochloride)

CAT N°: 31316
Price:

From 285.00 242.25

Bendamustine-d4 is intended for use as an internal standard for the quantification of bendamustine (Item No. 23693) by GC- or LC-MS. Bendamustine is a purine analog and DNA alkylating agent.{41416} It inhibits growth of SKW-3, Reh, CML-T1, BV-173, and HL-60 leukemia cell lines (IC50s = 27.0, 28.6, 15.6, 20.8, and 57.7 ?M, respectively) but not MCF-7 and MDA-MB-231 breast cancer cell lines (IC50s = >200 ?M for both).{41417} It is cytotoxic to patient-derived lymphocytic leukemia (B-CLL) cells (LD50s = 6.8-8.3 mg/ml).{41418} Bendamustine (50 mg/kg) inhibits tumor growth by 9 and 96% alone and in combination with ofatumumab, respectively, in a JVM-3 CLL mouse xenograft model.{41419} It activates the DNA-damage stress response, the base excision DNA repair pathway, and apoptosis, as well as inhibits mitotic checkpoints and induces mitotic catastrophe.{41416} Formulations containing bendamustine have been used to treat CLL and non-Hodgkin lymphoma.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 4-(5-((2-chloroethyl)(2-chloroethyl-1,1,2,2-d4)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid, monohydrochloride
  • Correlated keywords
    • 2070015-32-4 deuterated deuterium GCMS LCMS SKW-3 CMLT1 BV173 HL60 CMLT-1 MCF7 MDAMB MDAMB231 MB231 BCLL JVM3 SDX105
  • Product Overview:
    Bendamustine-d4 is intended for use as an internal standard for the quantification of bendamustine (Item No. 23693) by GC- or LC-MS. Bendamustine is a purine analog and DNA alkylating agent.{41416} It inhibits growth of SKW-3, Reh, CML-T1, BV-173, and HL-60 leukemia cell lines (IC50s = 27.0, 28.6, 15.6, 20.8, and 57.7 ?M, respectively) but not MCF-7 and MDA-MB-231 breast cancer cell lines (IC50s = >200 ?M for both).{41417} It is cytotoxic to patient-derived lymphocytic leukemia (B-CLL) cells (LD50s = 6.8-8.3 mg/ml).{41418} Bendamustine (50 mg/kg) inhibits tumor growth by 9 and 96% alone and in combination with ofatumumab, respectively, in a JVM-3 CLL mouse xenograft model.{41419} It activates the DNA-damage stress response, the base excision DNA repair pathway, and apoptosis, as well as inhibits mitotic checkpoints and induces mitotic catastrophe.{41416} Formulations containing bendamustine have been used to treat CLL and non-Hodgkin lymphoma.

We also advise you